Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Phase II study of docetaxel and vinorelbine as adjuvant chemotherapy for resected non-small cell lung cancers.

Chaft JE, Rekhtman N, Sima CS, Rusch V, Kris MG, Zakowski M, Azzoli CG.

Cancer Chemother Pharmacol. 2013 Oct;72(4):931-4. doi: 10.1007/s00280-013-2263-1.

2.

Pilot study of sequential vinorelbine and cisplatin followed by docetaxel for selected IIIB and stage IV non-small cell lung cancer.

Clark JI, Kancharla K, Qamar R, Fisher S, Hantel A, Panganiban J, Millbrandt L, Albain KS.

Lung Cancer. 2001 Nov;34(2):271-7.

PMID:
11679186
3.

Phase II study of adjuvant vinorelbine and cisplatin in Japanese patients with completely resected stage II and III non-small cell lung cancer.

Sonobe M, Okubo K, Teramukai S, Yanagihara K, Sato M, Sato T, Chen F, Sato K, Fujinaga T, Shoji T, Omasa M, Sakai H, Miyahara R, Bando T, Date H.

Cancer Chemother Pharmacol. 2014 Dec;74(6):1199-206. doi: 10.1007/s00280-014-2595-5.

PMID:
25253046
4.

Phase II randomized multicenter study evaluating a treatment regimen alternating docetaxel and cisplatin-vinorelbine with a cisplatin-vinorelbine control group in patients with stage IV non-small-cell lung cancer: GFPC 97.01 study.

Pérol M, Léna H, Thomas P, Robinet G, Fournel P, Coste E, Belleguic C, Le Caer H, Blanchon F, Vergnenègre A, Vernejoux JM, Schuller-Lebeau MP, Pham E.

Ann Oncol. 2002 May;13(5):742-7.

PMID:
12075743
5.

A randomized trial comparing adjuvant chemotherapy with gemcitabine plus cisplatin with docetaxel plus cisplatin in patients with completely resected non-small-cell lung cancer with quality of life as the primary objective.

Barlesi F, Chouaid C, Crequit J, Le Caer H, Pujol JL, Legodec J, Vergnenegre A, Le Treut J, Fabre-Guillevin E, Loundou A, Auquier P, Simeoni MC, Thomas PA.

Interact Cardiovasc Thorac Surg. 2015 Jun;20(6):783-90. doi: 10.1093/icvts/ivv050.

PMID:
25765952
6.

Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial.

Douillard JY, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonzáles-Larriba JL, Grodzki T, Pereira JR, Le Groumellec A, Lorusso V, Clary C, Torres AJ, Dahabreh J, Souquet PJ, Astudillo J, Fournel P, Artal-Cortes A, Jassem J, Koubkova L, His P, Riggi M, Hurteloup P.

Lancet Oncol. 2006 Sep;7(9):719-27. Erratum in: Lancet Oncol. 2006 Oct;7(10):797.

PMID:
16945766
7.

Induction chemotherapy with cetuximab, vinorelbine-cisplatin followed by thoracic radiotherapy and concurrent cetuximab, vinorelbine-cisplatin in patients with unresectable stage III non-small cell lung cancer.

Liu D, Zheng X, Chen J, Liu G, Xu Y, Shen Y, Xie L, Zhao W, Jiang G, Fan M.

Lung Cancer. 2015 Sep;89(3):249-54. doi: 10.1016/j.lungcan.2015.06.004.

PMID:
26118463
9.

Oral vinorelbine and cisplatin with concurrent radiotherapy after induction chemotherapy with cisplatin and docetaxel for patients with locally advanced non-small cell lung cancer: the GFPC 05-03 study.

Descourt R, Vergnenegre A, Barlesi F, Lena H, Fournel P, Falchero L, Berard H, Hureaux J, Le Caer H, Chavaillon JM, Geriniere L, Monnet I, Chouabe S, Robinet G; GFPC VINCR Team..

J Thorac Oncol. 2011 Feb;6(2):351-7. doi: 10.1097/JTO.0b013e318200f47e.

10.

Induction chemotherapy with triweekly docetaxel and cisplatin followed by concomitant chemoradiotherapy with or without surgery in stage III non-small-cell lung cancer: a phase II study.

Aydiner A, Sen F, Saglam EK, Oral EN, Eralp Y, Tas F, Toker A, Dilege S.

Clin Lung Cancer. 2011 Sep;12(5):286-92. doi: 10.1016/j.cllc.2011.03.030.

PMID:
21729649
11.

Docetaxel in combination with platinums (cisplatin or carboplatin) in advanced and metastatic non-small cell lung cancer.

Belani CP; TAX 326 Study Group..

Semin Oncol. 2002 Jun;29(3 Suppl 12):4-9. Review.

PMID:
12170445
12.

Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer.

Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, Cormier Y, Goss G, Inculet R, Vallieres E, Fry W, Bethune D, Ayoub J, Ding K, Seymour L, Graham B, Tsao MS, Gandara D, Kesler K, Demmy T, Shepherd F; National Cancer Institute of Canada Clinical Trials Group.; National Cancer Institute of the United States Intergroup JBR.10 Trial Investigators..

N Engl J Med. 2005 Jun 23;352(25):2589-97.

13.

Sequential two-line strategy for stage IV non-small-cell lung cancer: docetaxel-cisplatin versus vinorelbine-cisplatin followed by cross-over to single-agent docetaxel or vinorelbine at progression: final results of a randomised phase II study.

Douillard JY, Gervais R, Dabouis G, Le Groumellec A, D'Arlhac M, Spaeth D, Coudert B, Caillaud D, Monnier A, Clary C, Maury B, Mornet M, Rivière A, Clouet P, Couteau C.

Ann Oncol. 2005 Jan;16(1):81-9.

PMID:
15598943
14.

Split-dose cisplatin and vinorelbine as adjuvant chemotherapy for completely resected non-small cell lung cancer.

Hirai F, Seto T, Shimokawa M, Inamasu E, Toyozawa R, Toyokawa G, Yoshida T, Shiraishi Y, Takenaka T, Yamaguchi M, Takenoyama M, Ichinose Y.

Anticancer Res. 2014 Feb;34(2):927-31.

PMID:
24511034
15.

GILT--A randomised phase III study of oral vinorelbine and cisplatin with concomitant radiotherapy followed by either consolidation therapy with oral vinorelbine and cisplatin or best supportive care alone in stage III non-small cell lung cancer.

Flentje M, Huber RM, Engel-Riedel W, Andreas S, Kollmeier J, Staar S, Dickgreber N, Vaissiere N, De Almeida C, Edlich B, Fietkau R.

Strahlenther Onkol. 2016 Apr;192(4):216-22. doi: 10.1007/s00066-016-0941-8.

PMID:
26809652
16.

Evaluation of the safety and compliance of 3-week cycles of vinorelbine on days 1 and 8 and cisplatin on day 1 as adjuvant chemotherapy in Japanese patients with completely resected pathological stage IB to IIIA non-small cell lung cancer: a retrospective study.

Shukuya T, Takahashi T, Tamiya A, Ono A, Igawa S, Tsuya A, Nakamura Y, Murakami H, Naito T, Kaira K, Endo M, Yamamoto N.

Jpn J Clin Oncol. 2009 Mar;39(3):158-62. doi: 10.1093/jjco/hyn147.

PMID:
19139038
17.

Oral vinorelbine and cisplatin with concomitant radiotherapy in stage III non-small cell lung cancer (NSCLC): a feasibility study.

Beckmann G, Fietkau R, Huber RM, Kleine P, Schmidt M, Semrau S, Aubert D, Fittipaldo A, Flentje M.

Onkologie. 2006 Apr;29(4):137-42.

PMID:
16601369
18.

Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study.

Kubota K, Kawahara M, Ogawara M, Nishiwaki Y, Komuta K, Minato K, Fujita Y, Teramukai S, Fukushima M, Furuse K; Japan Multi-National Trial Organisation..

Lancet Oncol. 2008 Dec;9(12):1135-42. doi: 10.1016/S1470-2045(08)70261-4.

PMID:
19013107
19.

Gemcitabine and vinorelbine followed by weekly docetaxel in patients with advanced non-small-cell lung cancer: a phase II trial of sequential chemotherapy.

Cobo Dols M, Villar Chamorro E, Alés Díaz I, Gil Calle S, Alcalde García J, Gutiérrez Calderón V, Carabantes Ocón F, Montesa Pino A, Bretón García JJ, Benavides Orgaz M.

Clin Transl Oncol. 2006 Oct;8(10):742-9.

PMID:
17074673
20.

A retrospective comparison of adjuvant chemotherapeutic regimens for non-small cell lung cancer (NSCLC): paclitaxel plus carboplatin versus vinorelbine plus cisplatin.

Chang WJ, Sun JM, Lee JY, Ahn JS, Ahn MJ, Park K.

Lung Cancer. 2014 Apr;84(1):51-5. doi: 10.1016/j.lungcan.2014.01.017.

PMID:
24521819

Supplemental Content

Support Center